1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

Prequalification of HIV/AIDS Drugs - UN joint activity lPartners* –UNAIDS –UNICEF –UNFPA –WHO –With the support of World Bank lWHO –Manages, provides technical.
Lynda Paleshnuik | May Copenhagen Workshop May 2014 Session outlines and objectives L. Paleshnuik Lead Quality Assessor PQT.
…………………Country National Stakeholders Consultation Meeting dd/mm/yy
1 TG Dekker – WHO, MalaysiaFeb 2005 Dossier Requirements (quality part) Workshop on GMP and Quality Assurance of Multisource Tuberculosis Medicines Kuala.
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Finished Pharmaceutical Product Specifications
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Active Pharmaceutical Ingredient Master.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Variations Maintenance of Prequalified.
| Slide 1 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront Cape.
Variations to Prequalified Medicines Rutendo Kuwana Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
STABILITY STUDIES GABRIEL K. KADDU
TANZANIA August Note on Choice of Comparator Products: Current status Note to Applicants on Choice of Comparator Products in the Prequalification.
Variations to a prequalified product Hua YIN Prequalification of Medicines Programme QSM / EMP / HSS WHO Prequalification Programme: Training workshop.
1 WHO Procurement, Quality and Sourcing Project: Access to Tuberculosis Drugs of Acceptable Quality Experience from the Evaluation of Drug Dossiers with.
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
1 GMP issues in Q assessment Wondiyfraw Worku Assessor 6 th CPH assessment training workshop, May 2014.
WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.
PREQUALIFICATION General overview and procedures
Structure of Dossier of Medicinal Product- Q part
Slide 1 WHO Prequalification Programme: Training workshop March 2010, Beijing Requirements on documentation of API and FPP quality and evaluation process.
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
WHO Prequalification – Medicines Finished Pharmaceutical Products Hua YIN
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
| Slide 1 of 33 April 2007 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront.
Documentation of bioequivalence Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October 2009.
Theo Dekker -- Jiaxing, China --September |2 | WHO workshop on Quality, good manufacturing practice and bioequivalence with a focus on antituberculotics.
Prequalification project Drs. Jan Welink. * Note to applicants on the choice of comparator products for the prequalification.
Bioequivalence and Bioavailability Working Group.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
1 TG Dekker – WHO, MalaysiaFeb 2005 Experience with Prequalification of Dossiers (quality part) Workshop on GMP and Quality Assurance of Multisource Tuberculosis.
Artemisinin combined medicines, Kampala, February |1 | Training workshop on regulatory requirements for registration of Artemisinin based combined.
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
TECHNICAL REQUIREMENTS FOR MINOR APPLICATIONS E MOKANTLA 3 SEPTEMBER 2013.
Update on prequalification of medicines Dr Lembit Rägo Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and Pharmaceuticals.
DEPARTMENT OF HEALTH Medicines Regulatory Affairs
Meeting for EU Generic Manufacturers and EU MA holders for generic medicines, Copenhagen, 26 November 2009 Generics approved by stringent regulatory authorities:
Lynda Paleshnuik | January |1 | Quality Workshop Copenhagen – January 2012 Training session Outline and Objectives.
Theo Dekker -- CPH -- Nov |2 | Meeting of WHO PQP with European manufacturers and EU holders of marketing authorisations WHO Prequalification of.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
PQP-overview & update January Prequalification of Medicines Overview & update Wondiyfraw Z. Worku WHO Prequalification of Medicines Programme Assessment.
Lynda Paleshnuik | January |1 | Assessment Workshop Copenhagen – January 2011 The new PQP quality guideline.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
Pogány - Tanzania 1/36 WHO Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence János Pogány, pharmacist, PhD consultant to.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
WHO Prequalification Programme Milan Smid, M.D., Ph.D. Prequalification Programme: Priority Essential Medicines.
Pogány - Hanoi 1/40 Training Workshop on Pharmaceutical Quality and Bioequivalence, January 2006 János Pogány, pharmacist, Ph.D. consultant.
TANZANIA AUGUST TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS.
Deficiencies in Bioequivalence dossiers Overview and Examples.
Dr. Pogány - Geneva 1/30 PREQUALIFICATION OF ANTIMALARIAL DRUG PRODUCTS János Pogány, pharmacist, Ph.D. Geneva, 03 May 2004
Dr. Pogány - WHO, Shanghai 1/62 Workshop on Quality Assurance and GMP of multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
1 |1 | WHO Prequalification – Medicines Assessments Andrew Chemwolo, Technical Officer Prequalification Team – Medicines Assessment.
INDEX WHAT IS ICH ? HISTORY INITIATION INTRODUCTION TOPICS QUALITY GUDILINES.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
Prequalification of essential medicines Technical Briefing Seminar
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Assessment of Medicines
The WHO Prequalification of Medicines Programme Dossier Assessment
Prequalification of HIV/AIDS products and manufacturers
Presentation transcript:

1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health Organization Training Workshop on Pharmaceutical Quality, GMP and Bioequivalence Kiev - Ukraine 3 to 7 October 2005 Theo Dekker, D.Sc., consultant to WHO Research Institute for Industrial Pharmacy North-West University, Potchefstroom, South Africa

2 TG Dekker – WHO, UkraineOctober 2005 Some abbreviations used in all presentations APIActive pharmaceutical ingredient BPBritish Pharmacopoeia CEPEU certificate of suitability CPPWHO-type Certificate of a Pharmaceutical Product EOIExpression of interest FDCFixed-dose combination FPPFinished pharmaceutical product ICHInternational Conference on Harmonization Int.Ph.International Pharmacopoeia IRInfrared Ph.Eur.European Pharmacopoeia SmPCSummary of product characteristics TBTuberculosis USPUnited States Pharmacopeia XRPDX-ray powder diffractogram

3 TG Dekker – WHO, UkraineOctober 2005 Prequalification website

4 TG Dekker – WHO, UkraineOctober 2005 PQ Website – menu Bio group GMP group publication on QC testing Jan 06

5 TG Dekker – WHO, UkraineOctober 2005 PQ Website – product dossiers Frequently asked questions  Which products do we prequalify?  What data and information needs to be submitted in a dossier for a generic product?  What data and information needs to be submitted in a dossier for an innovator product?  What does a manufacturer have to submit to prove efficacy of a multi-source generic product?  How often are dossiers assessed? Click on question to get to answer

6 TG Dekker – WHO, UkraineOctober 2005 PQ Website – menu Bio group GMP group publication on QC testing Jan 06 ✔

7 TG Dekker – WHO, UkraineOctober 2005 Guidelines for submission (from web) 1 2

8 TG Dekker – WHO, UkraineOctober 2005 Guideline (“Main”) FPPs not approved by ICH/associated DRA Guideline on Submission of Documentation for Prequalification of Multisource (Generic) Finished Pharmaceutical Products (FPPs) used in the Treatment of HIV/AIDS, Malaria and Tuberculosis (“main guideline”, hand-out) Based on Marketing Authorization of Pharmaceutical Products with special Reference to Multisource (Generic) Products: a Manual for a Drug Regulatory Authority (WHO Blue Book, current edition)

9 TG Dekker – WHO, UkraineOctober 2005 Multisource products: Blue Book  Multisource products are pharmaceutically equivalent  Pharmaceutically equivalent products  Contain the same API(s) in the same amount(s) in the same dosage form  Meet similar quality standards  Are intended for the same route of administration  Multisource products that are therapeutically equivalent are interchangeable

10 TG Dekker – WHO, UkraineOctober 2005 Main guideline Administrative 1/50 A:Covering letter by responsible person  Statement: information is true and correct B:Application (Product dossier)  Four main sections (with subsections)  Keep to the sections/subsections as prescribed  Sections/subsections should be clearly marked preferably with securely fixed tags  Number all pages (essential)  Table of contents List sections, subsections – with page numbers

11 TG Dekker – WHO, UkraineOctober 2005 Main Guideline Dossier requirements – main sections Section 1 Characteristics of the FPP (3/50) Section 2 Active Pharmaceutical Ingredients (APIs) (4/50) Section 3 Finished Pharmaceutical Products (FPPs) (10/50) Section 4 Interchangeability (Bioequivalence) (25/50)

12 TG Dekker – WHO, UkraineOctober 2005 Main guideline Annexes Annex 1: Model Certificate of a Pharmaceutical Product 27/50 Annex 2: Model Batch Certificate of a Pharmaceutical Product 31/50 Annex 3: Model Stability Report of Active Pharmaceutical Ingredient (API) 33/50 Annex 4: Model Stability Report of Capsules/Tablets 36/50 Annex 5: Suggested Structure of the Summary of Product Characteristics (SmPC) 40/50 Annex 6: Suggested structure of the Package Information Leaflet (PIL) 43/50 Annex 7: Recommended presentation of bioequivalence trial information 45/50

13 TG Dekker – WHO, UkraineOctober 2005 Main guideline: Supplements Supplement 1 Guideline on Submission of Documentation for Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDS, Malaria and Tuberculosis Dissolution Testing for use from July 2005 (CPH25)

14 TG Dekker – WHO, UkraineOctober 2005 Main guideline: Supplements Supplement 2 Guideline on Submission of Documentation for Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDS, Malaria and Tuberculosis Extension of the WHO List of Stable (not easily degradable ARV) APIs (for stability testing) for use from July 2005 (CPH25)

15 TG Dekker – WHO, UkraineOctober 2005 Guideline FPPs approved by ICH & associated DRAs Guide on Submission of Documentation for Prequalification of Finished Pharmaceutical Products (FPPs) used in the treatment of HIV/AIDS, malaria and tuberculosis and approved by Drug Regulatory Authorities (DRAs) in the International Conference on Harmonization (ICH) region and associated countries, including inter alia the EU, Japan and USA

16 TG Dekker – WHO, UkraineOctober 2005 PQ Website – menu Bio group GMP group publication on QC testing Jan 06 ✔ ✔

17 TG Dekker – WHO, UkraineOctober 2005 Guidelines: FDCs Fixed-Dose Combinations (FDCs) Draft guidelines for registration of fixed-dose combination medicinal products (WHO, 2005) comprehensive on all aspects of safety, efficacy and quality Scientific and Technical Principles for Fixed Dose Combination Drug Products for Treatment of HIV/AIDS, Malaria, and Tuberculosis (HHS, UNAIDS, WHO & SADC, 2004) (“Botswana Principles”)

18 TG Dekker – WHO, UkraineOctober 2005 ICH guidelines ICH guidelines are used when a quality aspect cannot be (fully) assessed by the WHO guidelines, for instance:  Q3A(R). Impurities in new drug substances  Q3B(R). Impurities in new drug products  Q3C. Impurities: Guideline for residual solvents  Q6A. Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances (with decision trees)

19 TG Dekker – WHO, UkraineOctober 2005 Prequalification project Variation Guideline To be published soon on PQ website  The prequalification process is dynamic, taking into account that changes to the original dossier may become necessary during the lifetime of the product  Any changes or variations may involve administrative and/or more substantial changes and are subject to approval within the prequalification program

20 TG Dekker – WHO, UkraineOctober 2005 Prequalification project Variation Guideline (2)  ANNEX I  List of minor changes The conditions which must apply is stipulated The relevant part of the dossier to be resubmitted or updated, with the documentation required, is listed  ANNEX II  Lists major changes in general  ANNEX III  Lists types of changes which may require a new application

21 TG Dekker – WHO, UkraineOctober 2005 Closing remarks 1.The dossier submitted must conform to the requirements set out in the current WHO guidelines, as posted on web 2.The assessment of quality and safety/efficacy data presented is based on the current WHO guidelines 3.ICH guidelines are used when a quality aspect cannot be assessed by the WHO guidelines 4.The quality assessment includes variations or changes to already prequalified products